Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma

Condition:   Multiple Myeloma Interventions:   Drug: Belantamab mafodotin;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials